Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

BackgroundManaging the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency. Cytokine profiles could identify cases at risk of severe disease.MethodsWe designed a randomized phase II clinical trial to determine whether the combination of ruxolitinib (5 mg twice a day for 7 day...

Full description

Bibliographic Details
Main Authors: Jesus Garcia-Donas, Diego Martínez-Urbistondo, Kyra Velázquez Kennedy, Paula Villares, Arántzazu Barquin, Andrea Dominguez, Juan Francisco Rodriguez-Moreno, Elena Caro, Rafael Suarez del Villar, Estanislao Nistal-Villan, Monica Yagüe, Maria Ortiz, Maria Barba, Sergio Ruiz-Llorente, Miguel Quiralte, Massimiliano Zanin, Cristina Rodríguez, Paloma Navarro, Pedro Berraondo, Rodrigo Madurga
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Immunology
Subjects:
COVID19
SARS-Cov-2
cytokine storm
ruxolitinib
simvastatin
clinical trial
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1156603/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1156603/full

Similar Items